Viewing Study NCT00005027



Ignite Creation Date: 2024-05-05 @ 11:20 AM
Last Modification Date: 2024-10-26 @ 9:04 AM
Study NCT ID: NCT00005027
Status: COMPLETED
Last Update Posted: 2013-04-05
First Post: 2000-04-06

Brief Title: Rebeccamycin Analog in Treating Patients With Advanced Kidney Cancer
Sponsor: Barbara Ann Karmanos Cancer Institute
Organization: Barbara Ann Karmanos Cancer Institute

Study Overview

Official Title: A Phase II Study of Rebeccamycin Analog in Renal Cell Cancer
Status: COMPLETED
Status Verified Date: 2013-04
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: RATIONALE Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die

PURPOSE Phase II trial to study the effectiveness of rebeccamycin analog in treating patients who have advanced kidney cancer
Detailed Description: OBJECTIVES

Determine the response rate of patients with advanced renal cell carcinoma when treated with rebeccamycin analogue
Assess the quantitative and qualitative toxicities associated with this drug in this patient population

OUTLINE Patients receive rebeccamycin analogue IV over 30-60 minutes daily for 5 days Treatment continues every 21 days in the absence of disease progression or unacceptable toxicity

PROJECTED ACCRUAL A total of 23-44 patients will be accrued for this study within 9-18 months

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
U01CA062487 NIH None None
P30CA022453 NIH None None
WSU-C-2063 None None None
NCI-T99-0113 US NIH GrantContract None httpsreporternihgovquickSearchP30CA022453